HGH Fragment 176-191 and Semaglutide Interaction

Monitor
Mechanism-based 47% confidence

HGH Fragment 176-191 and Semaglutide have an interaction requiring monitoring for interaction with 47% confidence. Both HGH Fragment 176-191 and Semaglutide affect insulin sensitivity or blood glucose. Monitor fasting glucose and HbA1c. Consider adding an insulin sensitizer (metformin/berberine). Both compounds affect the gi tract and pancreas, so monitoring these systems is recommended.

Compound Profiles

HGH Fragment 176-191

Growth Hormone Fragment | Fat Loss Peptide

Mimics the lipolytic region of human growth hormone by stimulating fat breakdown through beta-3 adrenergic receptor pathways. Unlike full HGH, it does not bind the growth hormone receptor, so it does not increase IGF-1 levels or interfere with glucose metabolism.

Half-life: 15-20 minutes Typical dose: 250-500mcg weight loss, metabolic
carcinogenic riskinsulin disruptingteratogenic
View full profile

Semaglutide

GLP-1 Receptor Agonist | Weight Loss & Diabetes

Mimics native GLP-1, binding to receptors to stimulate glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying, and reduce appetite via hypothalamic pathways..

Half-life: ~7 days (168 hours) Typical dose: 0.25mg starting, titrate to 1-2.4mg weekly weight loss, metabolic
glp1 receptor carcinogenic riskinsulin disruptingteratogenic
View full profile

Combined Organ Load

GI Tract
low
Pancreas
low

Shared Safety Flags

2x 2 compounds share the carcinogenic-risk safety flag (HGH Fragment 176-191, Semaglutide). Monitor accordingly.
2x 2 compounds affect insulin sensitivity (HGH Fragment 176-191, Semaglutide). Monitor fasting glucose and HbA1c.
2x 2 compounds share the teratogenic safety flag (HGH Fragment 176-191, Semaglutide). Monitor accordingly.

Frequently Asked Questions

Can I take HGH Fragment 176-191 with Semaglutide?

Yes, but with caution. Both HGH Fragment 176-191 and Semaglutide affect insulin sensitivity or blood glucose. Monitor fasting glucose and HbA1c. Consider adding an insulin sensitizer (metformin/berberine). Regular monitoring is advised.

Is HGH Fragment 176-191 and Semaglutide safe together?

Based on pharmacological analysis, this combination is considered monitor. However, shared safety flags include: carcinogenic risk, insulin disrupting, teratogenic. Monitor accordingly.

What are the interactions between HGH Fragment 176-191 and Semaglutide?

Both HGH Fragment 176-191 and Semaglutide affect insulin sensitivity or blood glucose. Monitor fasting glucose and HbA1c. Consider adding an insulin sensitizer (metformin/berberine). This assessment has 47% confidence and is inferred from pharmacological mechanism analysis.

How should I time HGH Fragment 176-191 and Semaglutide?

HGH Fragment 176-191 has a half-life of 15-20 minutes and Semaglutide has a half-life of ~7 days (168 hours). No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

Check this pair in the full Interaction Checker Full comparison: HGH Fragment 176-191 vs Semaglutide

This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.